Ultragenyx Pharmaceutical Inc. enrolled only 12 patients in the pivotal phase III study of its recombinant human beta-glucuronidase (rhGUS) candidate, also known as UX003, to treat ultra-rare mucopolysaccharidosis 7 (MPS 7), or Sly syndrome.